Stockscreener 앱 받기
1.6095
0.31%
-0.0005
Gain Therapeutics Inc 주식(GANX)의 최신 뉴스
Gain Therapeutics Inc. Stock Analysis and ForecastMarket-crushing profits - Jammu Links News
What analysts say about Gain Therapeutics Inc. stockConsistent wealth multiplication - Jammu Links News
Bicara Therapeutics Inc. Stock Analysis and ForecastHigh-velocity gains - Jammu Links News
What analysts say about Gain Therapeutics Inc. stock outlookDefensive Stock Picks with Upside - Newser
Does Avalo Therapeutics Inc. stock pay reliable dividends200 Percent Gain Alert - Newser
Is Heron Therapeutics Inc. stock a good hedge against inflationDaily Gain Forecast - newser.com
Gain Therapeutics Announces $7 Million Public Offering - TipRanks
Form 424B5 Gain Therapeutics, Inc. - StreetInsider
Why Gain Therapeutics Inc. stock attracts strong analyst attentionDaily Stock Radar - beatles.ru
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering - The Manila Times
Gain Therapeutics on pricing stock-and-warrants offering - TradingView
Gain Therapeutics Secures $7M Funding to Advance Novel Parkinson's Treatment Pipeline - Stock Titan
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus - Benzinga
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics' High-Stakes Gamble: Can GT-02287 Rewrite the Neurodegenerative Treatment Playbook? - AInvest
Gain Therapeutics Plans Public Offering of Common Shares, Warrants - MarketScreener
Gain Therapeutics falls on equity offering plans - TradingView
Gain Therapeutics Announces Proposed Public Offering - The Manila Times
Gain Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Canada
Gain Therapeutics stock falls after announcing public offering - Investing.com
Gain Therapeutics, Inc. Proposes Underwritten Public Offering of Common Stock and Warrants - Quiver Quantitative
Gain Therapeutics Unveils Strategic Public Offering: Funding Next-Gen Parkinson's Treatment Development - Stock Titan
Why Alaunos Therapeutics Inc. stock attracts strong analyst attentionRapid Gain Targets - Newser
How Atossa Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
What makes Gain Therapeutics Inc. stock price move sharplyReturn Optimized Trade Insights - Newser
What makes Akero Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
Why Sangamo Therapeutics Inc. stock attracts strong analyst attentionDaily Gain Forecast - Newser
What makes Tango Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
What makes Spero Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
How Gain Therapeutics Inc. stock performs during market volatilityMomentum Swing Watchlist - Newser
What makes Lexeo Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
Why Cabot Corporation stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
Why Design Therapeutics Inc. stock attracts strong analyst attentionFree Stock Investment Growth Plan - beatles.ru
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Consensus Target Price from Brokerages - Defense World
Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight - The Malaysian Reserve
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Gain Therapeutics (GANX) and Edwards Lifesciences (EW) - The Globe and Mail
Parkinson's Disease Pipeline Appears Robust With 130+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - Menafn.com
Institutional investors are Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) biggest bettors and were rewarded after last week's US$47m market cap gain - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations - Investing.com India
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation - TradingView
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Gain Therapeutics Doubles Authorized Common Stock Shares - TipRanks
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
SpringWorks Therapeutics (SWTX) Continues Strong Yearly Run, Showing Over 29% YTD Gain - Daily Chhattisgarh News
Aquestive stock gains on FDA review for allergy drug (AQST) - Seeking Alpha
Stellantis (NYSE:STLA) Receives Consensus Rating of “Hold” from Analysts - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pharmaceutical Stocks Worth Watching – June 13th - Defense World
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance
Gain Therapeutics to Participate in Upcoming Investor Conferences - Bluefield Daily Telegraph
Gain Therapeutics Opens Access to Management: CEO Featured at Two Major Biotech Investor Conferences - Stock Titan
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha
0.86%
0.10%
자본화:
|
볼륨(24시간):